Results 71 to 80 of about 7,693 (199)

From senescence and inflammaging to systemic comorbidities: Drivers of aging‐associated periodontitis

Periodontology 2000, EarlyView.
Abstract Background Aging is accompanied by a chronic low‐grade inflammatory process, known as inflammaging, as well as immunosenescence, an age‐related decline and dysregulation of immune function, and cellular senescence, a process in which cells enter a state of irreversible growth arrest while actively releasing pro‐inflammatory factors.
James Cheng, Chew Tin Zar Aung, Samuel F. Suslavich, Sinem Esra Sahingur, Yvonne L. Hernandez‐Kapila   +4 more
wiley   +1 more source

Low molecular weight compounds from mushrooms as potential Bcl-2 inhibitors: docking and virtual screening studies [PDF]

, 2016
Mestrado com dupla diplomação com o Institut Superieur de Biotechnologie de MonastirMushrooms have the ability to promote apoptosis in tumor cell lines, but the mechanism of action is not quite well understood. Inhibition of the interaction between Bcl-2
Khelifa, Sabrine
core  

Senolytics and exercise: Dual modalities for rejuvenating muscle

The Journal of Physiology, EarlyView.
Abstract figure legend The role of senolytics on the heart and skeletal muscle. Senescent cell burden increases with ageing, disuse and disease. The senolytics dasatinib+quercetin (D+Q), navitoclax and fisetin, as well as exercise, eliminate senescent cells, reducing senescent cell burden and their senescence‐associated secretory phenotype (SASP ...
Zeynep Elif Yesilyurt‐Dirican, Ce Qi, Uchenna Okpechi, Maya Strand Ford, Georgina M. Ellison‐Hughes   +4 more
wiley   +1 more source

Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides

Advanced Science, Volume 13, Issue 26, 8 May 2026.
Single‐cell RNA analyses of paired lesions from CD30+ mycosis fungoides patients demonstrate that brentuximab vedotin (BV) induces immunogenic cell death in both CD30+ and CD30− malignant T cells. BV also targets regulatory T cells and remodels tumor microenvironment, while resistance is driven by impaired IFN responses, drug efflux, and BCL2 ...
Yi Jiang, Pan Lai, Mingjia Li, Yujie Wen, Mengzhou Cao, Yu Xiao, Zhuojing Chen, Jingru Sun, Yang Wang   +8 more
wiley   +1 more source

From Mitochondrial Biology to Magic Bullet: Navitoclax Disarms BCL-2 in Chronic Lymphocytic Leukemia [PDF]

Journal of Clinical Oncology, 2012
Navitoclax is a selective small-molecule B-cell lymphoma 2 (BCL-2)/BCL-XL inhibitor that represents both the fruition of nearly three decades of BCL-2 protein research and the promise of a new generation of targeted therapeutics for reactivating apoptosis in cancer.
openaire   +2 more sources

Navitoclax (ABT-263) Accelerates Apoptosis during Drug-Induced Mitotic Arrest by Antagonizing Bcl-xL [PDF]

Cancer Research, 2011
Abstract Combining microtubule-targeting antimitotic drugs with targeted apoptosis potentiators is a promising new chemotherapeutic strategy to treat cancer. In this study, we investigate the cellular mechanism by which navitoclax (previously called ABT-263), a Bcl-2 family inhibitor, potentiates apoptosis triggered by paclitaxel and ...
Jue, Shi, Yuan, Zhou, Hsiao-Chun, Huang, Timothy J, Mitchison   +3 more
openaire   +2 more sources

Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW. [PDF]

, 2017
Purpose: B-cell lymphomas must acquire resistance to apoptosis during their development. We recently discovered BCLW, an antiapoptotic BCL2 family member thought only to contribute to spermatogenesis, was overexpressed in diffuse large B-cell lymphoma ...
Adams, Clare M., Eischen, Christine M., Gong, MD, Jerald Z., Mitra, Ramkrishna   +3 more
core   +1 more source

Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. [PDF]

, 2016
Protein-protein interactions (PPIs) are of pivotal importance in the regulation of biological systems and are consequently implicated in the development of disease states.
A Ciulli, A Degterev, A Oberstein, A Patel, A Patel, A Shaginian, A Turnbull, A Winter, AA Bogan, AA Lugovskoy, AB Mahon, AC Braisted, AD Morley, AF Donnell, AG Coyne, AJ Souers, AL Jochim, AM Petros, AM Petros, Andrew R. Bayly, AP Higueruelo, AR Bayly, AV Follis, B Ku, B Lehner, B Ma, B Padmanabhan, BC Raimundo, BE Sleebs, BL Grasberger, C Tse, C Zhuang, CA Lepre, CD Thanos, CG Wilson, CH Arrowsmith, CH Kenny, Chris Abell, CQ Wei, CQ Wei, D Cox, D Grimme, D Marcotte, D Rognan, D Seebach, D Szklarczyk, DA Erlanson, DC Fry, DE Scott, DE Scott, DI Hammoudeh, DJ Craik, DJ Huggins, DK Johnson, Duncan E. Scott, EF Lee, EF Lee, EF Lee, F Christ, F Cossu, F Falchi, FB Sheinerman, FP Davis, G Wang, G Zimmermann, GR Bickerton, H Jhoti, H Jubb, H Karatas, H Sun, H Wu, H Yin, H Zhou, HL Perez, HP Sun, HY Sun, I Monfardini, I Navratilova, I Van Molle, IJ Enyedy, J Hyde, J Liu, JA Kritzer, JA Wells, JB Baell, JC Fuller, JD Sadowsky, JG Allen, JL Wang, JM Davis, John Skidmore, JW Huang, JW Tilley, K Sauve, KI Tong, L Chen, L Hu, L Pellegrini, LD Walensky, LD Walensky, LK Henchey, LM Meireles, LT Vassilev, M Bruncko, M Rickert, M Sattler, M Vogler, M Whittaker, MC Lo, MC Smith, MD Wendt, MJ Basse, MJ de Vega, ML Stewart, MR Arkin, MR Arkin, N Sugaya, O Ichihara, O Keskin, O Keskin, O Mirguet, P Chakrabarti, P Filippakopoulos, P Filippakopoulos, P Mukherjee, P Sledz, P Walter, PJ Hajduk, PJ Hajduk, PJ Real, PW White, Q Cai, Q Chu, QC Zhang, R Hancock, R Hancock, RF Kester, RJ Bienstock, RJ Robb, S Barelier, S Ducki, S Ferrari, S Fletcher, S Fletcher, S Jones, S Miller, SC Lo, SD Furdas, SM Biros, SM Srinivasula, SP Brown, T Clackson, TA Larsen, TG Davies, TJ Blackburn, TK Oost, TL Blundell, TL Blundell, TS Peat, VS Rao, W Antuch, WA Loughlin, WB Turnbull, X Morelli, XQ Liu, Y Chen, Y Huang, Y Tanaka, Y Zhao, YS Tan, Z Hu, ZY Jiang   +171 more
core   +2 more sources

CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216

Blood Advances, 2023
Abstract Acute megakaryoblastic leukemia (AMKL) is a rare, developmentally restricted, and highly lethal cancer of early childhood. The paucity and hypocellularity (due to myelofibrosis) of primary patient samples hamper the discovery of cell- and genotype-specific treatments.
Verena Gress, Mathieu Roussy, Luc Boulianne, Mélanie Bilodeau, Sophie Cardin, Nehme El-Hachem, Véronique Lisi, Banafsheh Khakipoor, Alexandre Rouette, Azer Farah, Louis Théret, Léo Aubert, Furat Fatima, Éric Audemard, Pierre Thibault, Éric Bonneil, Jalila Chagraoui, Louise Laramée, Patrick Gendron, Loubna Jouan, Safa Jammali, Bastien Paré, Shawn M. Simpson, Thai Hoa Tran, Michel Duval, Pierre Teira, Henrique Bittencourt, Raoul Santiago, Frédéric Barabé, Guy Sauvageau, Martin A. Smith, Josée Hébert, Philippe P. Roux, Tanja A. Gruber, Vincent-Philippe Lavallée, Brian T. Wilhelm, Sonia Cellot   +36 more
openaire   +3 more sources

Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics

Cells, 2022
A first-line therapeutic for high-grade glioma, notably glioblastoma (GBM), is the DNA methylating drug temozolomide (TMZ). Previously, we showed that TMZ induces not only apoptosis and autophagy, but also cellular senescence (CSEN).
Lea Beltzig, Markus Christmann, Bernd Kaina   +2 more
doaj   +1 more source